[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU784988B2 - Lentiviral vector transduction of hematopoietic stem cells - Google Patents

Lentiviral vector transduction of hematopoietic stem cells Download PDF

Info

Publication number
AU784988B2
AU784988B2 AU15944/01A AU1594401A AU784988B2 AU 784988 B2 AU784988 B2 AU 784988B2 AU 15944/01 A AU15944/01 A AU 15944/01A AU 1594401 A AU1594401 A AU 1594401A AU 784988 B2 AU784988 B2 AU 784988B2
Authority
AU
Australia
Prior art keywords
stem cells
cells
vector
population
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU15944/01A
Other languages
English (en)
Other versions
AU1594401A (en
Inventor
Wen Yong Chen
John C. Kappes
Tim M. Townes
Xiaoyun Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU1594401A publication Critical patent/AU1594401A/en
Application granted granted Critical
Publication of AU784988B2 publication Critical patent/AU784988B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU15944/01A 1999-11-10 2000-11-10 Lentiviral vector transduction of hematopoietic stem cells Expired - Fee Related AU784988B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16462599P 1999-11-10 1999-11-10
US60/164625 1999-11-10
PCT/US2000/030882 WO2001034843A1 (en) 1999-11-10 2000-11-10 Lentiviral vector transduction of hematopoietic stem cells

Publications (2)

Publication Number Publication Date
AU1594401A AU1594401A (en) 2001-06-06
AU784988B2 true AU784988B2 (en) 2006-08-17

Family

ID=22595350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15944/01A Expired - Fee Related AU784988B2 (en) 1999-11-10 2000-11-10 Lentiviral vector transduction of hematopoietic stem cells

Country Status (5)

Country Link
EP (1) EP1230394A4 (de)
JP (1) JP2003517301A (de)
AU (1) AU784988B2 (de)
CA (1) CA2391129A1 (de)
WO (1) WO2001034843A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003012054A2 (en) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
RU2305708C2 (ru) * 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
ATE458047T1 (de) 2002-03-07 2010-03-15 Univ Delaware Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
CN103492406B (zh) 2010-12-09 2022-07-26 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
US20140199279A1 (en) * 2011-01-03 2014-07-17 Bluebird Bio, Inc. Methods for enhancing the delivery of gene-transduced cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015157252A1 (en) 2014-04-07 2015-10-15 BROGDON, Jennifer Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015183885A1 (en) * 2014-05-27 2015-12-03 Dana-Farber Cancer Institute, Inc. Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo
DK3280729T3 (da) 2015-04-08 2022-07-25 Novartis Ag Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
EP3512538A4 (de) * 2016-09-13 2020-05-06 Academia Sinica Verfahren zur verlängerung der lebensdauer und/oder zur behandlung von zellulären proliferativen störungen durch transplantation
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BODINE ET AL (1993) BLOOD. VOL 7 1975-1980 *
MIYOSHI ET AL (1999) SCIENCE VOL. 283:682-686 *
UCHIDA ET AL (1998) PROC.NATL.ACAD.SCI. VOL 95:11939-11944 *

Also Published As

Publication number Publication date
EP1230394A4 (de) 2002-12-18
CA2391129A1 (en) 2001-05-17
JP2003517301A (ja) 2003-05-27
AU1594401A (en) 2001-06-06
EP1230394A1 (de) 2002-08-14
WO2001034843A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
US20240336935A1 (en) Self-inactivating lentiviral vector comprising a foxp3 expression cassette
Moritz et al. Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease.
Puthenveetil et al. Successful correction of the human β-thalassemia major phenotype using a lentiviral vector
AU784988B2 (en) Lentiviral vector transduction of hematopoietic stem cells
Chen et al. Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice
KR101990068B1 (ko) 렌티바이러스 벡터의 안정한 제조
US8501464B2 (en) Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
Schambach et al. Lentiviral vectors pseudotyped with murine ecotropic envelope: increased biosafety and convenience in preclinical research
Vassilopoulos et al. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
EP1958648A1 (de) Therapeutisches verfahren für blutgerinnungsstörungen
JP2018519827A (ja) 逆配向のヒトユビキチンｃプロモーターを含むレトロウイルスベクター
EP3191596B1 (de) Lentiviraler vektor zur behandlung von hämoglobinerkrankungen
Tahara-Hanaoka et al. Lentiviral vector–mediated transduction of murine CD34− hematopoietic stem cells
KR101891626B1 (ko) 렌티바이러스 벡터의 반-안정성 산물
Douglas et al. Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis
Liu et al. Identification of parameters required for efficient lentiviral vector transduction and engraftment of human cord blood CD34+ NOD/SCID-repopulating cells
Jonuschies et al. The human desmin promoter drives robust gene expression for skeletal muscle stem cell-mediated gene therapy
EP4339291A1 (de) Lentivirale vektoren und verwendungen davon
Derdouch et al. Reconstitution of the myeloid and lymphoid compartments after the transplantation of autologous and genetically modified CD34+ bone marrow cells, following gamma irradiation in cynomolgus macaques
Mouly et al. CD4 regulation in human lymphoid non-T-cells: a role for the silencer element
EP2021484B1 (de) Expressionsvektoren mit dem hs1-promotor des onkogens vav1 und deren verwendung zur herstellung von pharmazeutischen zusammensetzungen für die somatische gentherapie
Tiwari Gene Therapy Approaches for Hemophagocytic Lymphohistiocytosis